Healthcare entity
BioLife Solutions is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 15.5 original sources on average, compared with 4.1 for the broader beat in this window. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category.
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
BioLife Solutions is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 15.5 original sources on average, compared with 4.1 for the broader beat in this window. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. The 6 average consequence score is above the beat benchmark of 5.6 in the same window. We currently track 2 Healthcare stories that mention Indivior, published between February 26, 2026 and February 27, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 70 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Indivior. Shared-story counts are live from our verified record — not editorial picks.
The fourth quarter of 2025 revealed a decisive shift in the healthcare technology sector toward AI-integrated diagnostics and high-margin specialized therapies. Leading the charge, Butterfly Network reported record revenue growth driven by its AI-embedded strategy, while Solventum navigated its post-spin-off stabilization phase with resilient organic growth.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Indivior is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
